iRhythm Technologies (IRTC) announced its acquisition of VitalConnect for approximately $287.5 million in cash and stock. This strategic move aims to immediately expand iRhythm's addressable market in cardiac monitoring, enhance its product portfolio, and accelerate commercial opportunities, with expected revenue growth accretion starting in 2027.
iRhythm Technologies (IRTC) is acquiring VitalConnect, a maker of wearable biosensors and ambulatory cardiac monitoring technology, for $287.5 million. This acquisition is a significant strategic move for IRTC, as it immediately expands their addressable market, particularly in ambulatory cardiac monitoring and multi-vitals monitoring, and provides an FDA-cleared platform. The deal is expected to create meaningful commercial acceleration opportunities by leveraging IRTC's existing sales infrastructure and broaden its market into inpatient and remote patient monitoring. While the transaction is expected to be accretive to IRTC's revenue growth rate starting in 2027, the immediate impact could be positive due to the expanded capabilities and market reach, offering a long-term growth opportunity for traders. The funding from existing cash on hand and stock component aligns VitalConnect stakeholders, but the integration risk and regulatory approval process (expected to close by end of 2026) are key considerations.